PharmaShots | Incisive News in 3 Shots

Subscribe Now

early breast cancer

Tanvex Reports Results of TX05 (biosimilar- trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

Tanvex Reports Results of TX05 (biosimilar- trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

February 20, 2021

Henlius Reports First Patient Dosing with HLX11 (biosimilar- pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Breast Cancer

Henlius Reports First Patient Dosing with HLX11 (biosimilar- pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Brea...

September 20, 2020

Roche's Kadcyla (trastuzumab emtansine) Receives FDA's Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US

Roche's Kadcyla (trastuzumab emtansine) Receives FDA's Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in...

May 6, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us